Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Glioblastoma 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Liver Cirrhosis 1Gliosarcoma 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Bevacizumab 23Sorafenib 20Doxorubicin 14Gemcitabine 11durvalumab 10Oxaliplatin 10Fluorouracil 10Cisplatin 10Capecitabine 9Nivolumab 8pembrolizumab 6Sunitinib 6tremelimumab 5atezolizumab 5Radiofrequency Ablation 5Neoadjuvant Therapy 5Leucovorin 5lenvatinib 4aldesleukin 4Thalidomide 4Radiotherapy 4Radiosurgery 4Everolimus 4Erlotinib Hydrochloride 4Drug Therapy 4Carboplatin 4toripalimab 3regorafenib 3camrelizumab 3apatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liver Neoplasms × fluoromisonidazole × Clear all
NCT02471313 2019-04-23

Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
3 enrolled 5 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡